SERPINC1 and Sepsis: We based our dosing regimen for non-activated ATIII on a baboon model of sepsis, in which ATIII administration between 10 to 20-fold the physiological level (2.4 μM) was required to initiate an anti-inflammatory response to prevent disseminated intravascular coagulation [34].